No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020
Related Articles
VibeRide | World’s First Longboard Brake
Welcome to VibeRide, home of the longboard brake. We’re group of guys from Salt Lake City who’s love of downhill skating sparked the idea for…
VibeRide | World’s First Longboard Brake
Welcome to VibeRide, home of the longboard brake. We’re group of guys from Salt Lake City who’s love of downhill skating sparked the idea for…
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
It is unclear whether the effect of canagliflozin on adverse kidney and cardiovascular events in those with diabetic kidney disease varies by age and sex.…
We Created the World’s First Longboard Brake
Once you try it, you’ll never go back. VibeRide.com BrakeBoard: VibeRide.com/products/drop-through-brakeboardOver the past 4 years, we set out to create the …
Introducing the World’s First Longboard Brake
Once you try it, you’ll never go back. VibeRide.com BrakeBoard: VibeRide.com/products/drop-through-brakeboardOver the past 4 years, we set out to create the …
Ozempic 3.0? Lilly’s ‘triple-G’ drug shows biggest weight loss yet in mid-stage trial
The battle to provide obesity treatments jumps to a new level, with Eli Lilly announcing that an experimental drug that acts on three hormones (rather…
HCM | Cardiometabolic CE
Surgical Considerations in Management of HCM May 17, 2023 | HCM1b) Our distinguished faculty is Hartzell Schaff, MD, @HSchaffMD, Cardiovascular Surgeon @MayoClinic, and President, American…
FDA Extends Dapagliflozin Indication Across LVEF Spectrum
The expanded approval is based on the positive results from DELIVER and mirrors last year’s decision for empagliflozin.
Patients and Physician Perspectives About Oral Anticoagulation in Patients With Atrial Fibrillation
This cohort study assesses the perceptions of patients with atrial fibrillation and their physicians about the benefits and risks of anticoagulation.